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Background: The economic sustainability of all areas of medicine is under scrutiny. Limited data exist on the
drivers of cost after a craniotomy for tumor resection (CTR). The objective of the present study was to develop and
validate a predictive model of hospitalization cost after CTR.
Methods: We performed a retrospective study involving CTR patients who were registered in the Nationwide
Inpatient Sample (NIS) database from 2005–2010. This cohort underwent 1:1 randomization to create derivation and
validation subsamples. Regression techniques were used for the creation of a parsimonious predictive model.
Results: Of the 36,433 patients undergoing CTR, 14638 (40.2%) underwent craniotomies for primary malignant,
9574 (26.3%) for metastatic, and 11414 (31.3%) for benign tumors. The median hospitalization cost was $24,504
(Interquartile Range (IQR), $4,265-$44,743). Common drivers of cost identified in the multivariate analyses included:
length of stay, number of procedures, hospital size and region, and patient income. The models were validated in
independent cohorts and demonstrated final R2 very similar to the initial models. The predicted and observed
values in the validation cohort demonstrated good correlation.
Conclusions: This national study identified significant drivers of hospitalization cost after CTR. The presented model
can be utilized as an adjunct in the cost containment debate and the creation of data-driven policies.
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The recent seismic changes in US healthcare are driven
by the push for economic sustainability of the system
[1,2]. Several value-based initiatives aim to minimize
cost in areas of increased spending and promote
rationalization of resource allocation [1]. Neurosurgical
procedures are associated with significant risks and high
hospitalization costs. Craniotomy for tumor resection
(CTR) is one of the most common such procedures, and
will be part of the cost containment debate. The estima-
tion of the hospitalization cost for each individual CTR
patient, and the identification of modifiable drivers of
cost could allow physicians to understand the economic
aspects of CTR, and modify their practice accordingly.* Correspondence: kbekelis@gmail.com
†Equal contributors
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unless otherwise stated.Future attempts at cost containment could focus on
these factors, rather than follow an arbitrary path.
Several studies have analyzed the cost-effectiveness of
different treatment modalities for brain tumors [3-10].
Others have examined the cost or charges of the
hospitalization after CTR [11,12]. The latter have limited
generalization since they are referring to single institu-
tions or regional experiences, demonstrating significant
selection bias. There is a paucity of national data on the
hospitalization cost of patients undergoing CTR, the
drivers of this cost, and predictive models at the level of
the individual patient.
The National Inpatient Sample (NIS) [13] is an all
payer, hospital discharge database that represents ap-
proximately 20% of all inpatient admissions to nonfed-
eral hospitals in the United States. It allows the
unrestricted study of the patient population in question.
Using this database, several socioeconomic variables, asentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cost variability after CTR were identified. Based on these
data, a predictive model of cost after CTR was developed
and validated in an independent cohort.
Methods
National Inpatient Sample (NIS) Database
All patients undergoing CTR, who were registered in the
National Inpatient Sample (NIS) [13] Database (Health-
care Cost and Utilization Project, Agency for Healthcare
Research and Quality, Rockville, MD) between 2005 and
2010, were included in the analysis. The NIS is an all-
payer prospective hospital discharge database that repre-
sents approximately 20% of all inpatient admissions to
nonfederal hospitals in the US. More information about
the NIS is available at http://www.ahcpr.gov/data/hcup/
nisintro.htm. This database contains de-identified data
(consents cannot be obtained), and has been deemed ex-
empt from IRB approval.
Cohort definition
In order to establish the cohort of patients, we used
International Classification of Disease-9-Current Modifi-
cation (ICD-9-CM) codes to identify patients in the
registry who underwent craniotomies (ICD-9-CM pro-
cedure code 01.51, 01.53, 0.59) for brain tumors (ICD-
CM diagnostic code 191.0, 191.1, 191.2, 191.3, 191.4,
191.5, 191.6, 191.7, 191.8, 191.9, 225.0, 225.1, 225.2,
237.5, 237.6, 237.6, 192.0, 192.1, 198.3, 200.5) between
2005 and 2010 (Figure 1). Patients on whom care was
withdrawn, or died during the hospitalization were ex-
cluded from the cohort.
Outcome variable
The primary outcome variable was the total hospitalization
cost after CTR. Cost data were obtained by conversion of
the hospital charges using the group-average cost-to-
charge ratio for each hospital in the database. Group-Figure 1 Cohort selection for the study.average cost-to-charge ratio and hospital charges are avail-
able in the NIS database. All costs were adjusted to their
2010 dollar value using the national consumer price index.
Exposure variables
The association of the outcome with the pertinent ex-
posure variables was examined in a multivariate analysis.
Age was a continuous variable. Gender, race (African
American, Hispanic, Asian, or other, with Caucasian be-
ing the reference value), insurance (private insurance,
self pay, Medicaid, with Medicare being the reference
value), and income (defined as the median income based
on zip code; income was divided into quartiles, with the
lowest quartile being the reference value) were categor-
ical variables.
The patient-level (Additional file 1: Table S1) comor-
bidities (categorical variables) were diabetes mellitus
(DM), tobacco exposure, hypertension, hyperlipidemia,
peripheral vascular disease (PVD), congestive heart fail-
ure (CHF), coronary artery disease (CAD), history of
prior ischemic stroke, obesity, chronic renal failure
(CRF), history of a TIA event, seizure disorder and coag-
ulopathy. A categorical variable was used for the type of
tumor resected (primary malignant tumor, metastasis,
benign tumor, and other). The patient-level postopera-
tive variables (categorical variables) were (Additional file
1: Table S1): treated hydrocephalus, hyponatremia, other
neurologic complications, deep vein thrombosis (DVT),
pulmonary embolism (PE), and acute renal failure
(ARF). Lastly, hospitalization specific factors (continuous
variables) were length-of-stay (LOS), number of proce-
dures performed (NPx), and number of admission diag-
noses (NDx).
The hospital characteristics used in the analysis as cat-
egorical variables included hospital region (West, South,
Midwest, with Northeast being the reference value), hos-
pital location (urban teaching, urban non-teaching, with
rural being the reference value), and hospital bed size
(medium, large, with small being the reference value).
More information of the definitions of the various cat-
egories of hospital characteristics can be found at http://
www.hcup-us.ahrq.gov/db/vars/nis_stratum/nisnote.jsp.
Statistical analysis
Continuous variables were presented with the mean and
standard deviation or median and interquartile range,
whereas categorical values were presented as percent-
ages. Continuous variables were compared using t-tests
or Mann–Whitney test, and categorical variables were
compared using Chi-square tests.
Initial analysis of cost data revealed significant positive
skewness and kurtosis and linear regression analysis using
cost resulted in a heteroskedastic variance of errors. In
order to achieve normality the data were transformed
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transformations attempted included square root, cube
root, and inverse transformation. These were not eventu-
ally used because the ln transformation provided the best
fit for the data. The ln transformation significantly im-
proved the skewness and kurtosis of the distributions
(skewness = 0.12, kurtosis = −0.049). Normality was also
assessed using histograms and Q-Q plots. The distribu-
tions of LOS, NDx, and NPx demonstrated significant
positive skewness and kurtosis as well, and were also ln
transformed before the analysis to achieve normality.
Our cohort was then randomized (1:1 randomization,
in order to create two 50% sub-samples) to a derivation
and a validation cohort. Subsequently, patients with
missing values were removed from the cohort using list-
wise deletion. A parsimonious model was then devel-
oped in the derivation cohort by performing a stepwise
linear regression including all the variables discussed
previously. Dummy variables were created for non-
binary categorical variables. The level of significance
used for retention in the model was 0.05. No colinearity
was observed by assessing tolerance and variance infla-
tion factor (VIF). The regression diagnostics performed
were the coefficient of determination (R2) and analysis of
the residuals. Normality among the distribution of resid-
uals was verified with histograms (Additional file 1: Figure
S1 and S2), and P-P plots (Additional file 1: Figure S3 and
S4). Further diagnostics included scatter plots of the stan-
dardized predicted values versus the standardized resid-
uals, which revealed a random, symmetric distribution of
values very close to zero (Additional file 1: Figure S5),
therefore suggesting a linear fit of data.
The model created in the derivation cohort was applied
on the validation cohort, the R2 was calculated and re-
sidual analysis was performed. The predicted values for
the validation cohort were plotted against the observed
values and goodness of fit was assessed. No heteroskedas-
ticity was observed. For reporting purposes, we back
transformed the data to demonstrate the percentage of
the contribution of each variable to the cost value.
All probability values are the results of two-sided tests,
and the level of significance was set at P < 0.05. Statis-
tical analyses were performed using SPSS version 20
(IBM, Armonk, NY), XLSTAT version 2013.6.02
(Addinsoft, New York, NY).
Results
Patient characteristics
In the selected study period there were 36,433 patients
(median age was 56.0 years, 53.3% females) undergoing
CTR who were registered in NIS. Of these patients,
14,638 (40.2%) presented with primary malignant brain tu-
mors, 9574 (26.3) with metastatic tumors, and 11414
(31.3%) with benign tumors (Table 1). Following 1:1randomization and subsequent listwise deletion, deriv-
ation and validation cohorts were created. Randomization
resulted in no significant differences in exposure factors
between these two subgroups (Table 1).
Primary outcome
The mean and median hospitalization cost for patients
undergoing CTR was $31,780 (95% CI, $31,518-$32,041)
and $24,504 (Interquartile Range (IQR), $4,265-$44,743),
respectively (Table 2a). Patients who were discharged
home (Table 2b) had a lower hospitalization cost (median
cost $21,735 (Interquartile Range (IQR), $15,514-
$31,481)) in comparison to patients discharged to short-
term care facilities (median cost $31,208 (Interquartile
Range (IQR), $21,403-$47,662)).
Model derivation
Several factors were included in our parsimonious
model after stepwise linear regression (Table 3). Hospi-
tals in the West and Midwest (45.5% and 16.1% more
respectively, in comparison to the Northeast), African-
Americans (3.9% more, in comparison to Caucasians),
hydrocephalus (9.3% more), coagulopathy (8.4% more),
post-operative neurologic complications (10.3% more), and
higher income (6.2% more for the highest income quartile,
in comparison to the lowest quartile) were associated with
increased hospitalization cost. A 1% increase in LOS, and
number of procedures was associated with a 0.5%, and
0.2% increase in cost, respectively. On the contrary,
hospitals in the South (5.7% less, in comparison to hos-
pitals in the Northeast), private insurance coverage
(4.0% less, in comparison to coverage by Medicare),
urban non-teaching hospitals (5.7% less, in comparison
to rural hospitals), and medium bed size (8.8% less, in
comparison to small hospitals) were associated with de-
creased cost. Our model could explain a significant por-
tion of the variance in cost with an R2 of 0.62.
Model validation
The model was validated in a random cohort of pa-
tients, and the final R2 did not differ more than 5%
from the initial values (R2 = 0.60). There was very good
association of the predicted values with the observed
values in the validation cohort (Figure 2) (Pearson’s rho =
0.77, P < 0.001).
Discussion
In this retrospective analysis of the NIS we developed a
predictive model of hospitalization cost after CTR, and
validated it in an independent cohort. The relative con-
tribution of individual drivers of hospitalization cost
after CTR have been identified. In a nation that spent
$2.4 trillion on health care in 2008 alone, expenditures
are under increasing scrutiny. A major component of
Table 1 Patient and hospital characteristics for patients undergoing craniotomy for tumor resection
All patients Derivation cohort Validation cohort P-Value*
Sample size 36,433 18,218 18,215
Median (IQR) Median (IQR) Median (IQR)
Age, median (IQR) 56 (23) 56 (23) 56 (22) 0.485
Length of Stay, median (IQR) 5 (6) 5 (6) 5 (6) 0.237
Number of Procedures, median (IQR) 2 (3) 2 (3) 2 (3) 0.060
Number of Diagnoses, median (IQR) 6 (5) 6 (5) 6 (5) 0.890
N (%) N (%) N (%)
Sex F 19406 (53.26) 9660 (53.02) 9746 (53.51) 0.358
M 17027 (46.74) 8558 (46.98) 8469 (46.49)
Tumor type Malignant primary 14638 (40.18) 7380 (40.51) 7258 (39.85) 0.197
Benign 11414 (31.33) 5716 (31.38) 5698 (31.28) 0.847
Metastatic 9574 (26.28) 4705 (25.83) 4869 (26.73) 0.051
Other 807 (2.22) 417 (2.28) 390 (2.14) 0.338
Region Northeast 7940 (21.79) 4017 (22.05) 3923 (21.54) 0.236
Midwest 5299 (14.54) 2656 (14.58) 2643 (14.51) 0.852
South 14259 (39.14) 7074 (38.83) 7185 (39.45) 0.229
West 8935 (24.52) 4471 (24.54) 4464 (24.51) 0.939
Payer Medicare 11274 (30.94) 5611 (30.80) 5663 (31.09) 0.549
Medicaid 3951 (10.84) 2025 (11.12) 1926 (10.57) 0.096
Private payer 18398 (50.50) 9241 (50.72) 9157 (50.27) 0.387
Self-payer 1413 (3.88) 653 (3.58) 760 (4.17) 0.004
Other 1397 (3.83) 688 (3.78) 709 (3.89) 0.565
All patients Derivation cohort Validation cohort P-Value*
N (%) N (%) N (%)
Race Caucasian 28225 (77.47) 14148 (77.66) 14077 (77.28) 0.389
African-American 2874 (7.89) 1382 (7.59) 1492 (8.19) 0.032
Hispanic 3123 (8.57) 1576 (8.65) 1547 (8.49) 0.591
Asian 978 (2.68) 505 (2.77) 473 (2.60) 0.301
Other 1233 (3.38) 607 (3.33) 626 (3.44) 0.580
Location Rural 875 (2.40) 433 (2.38) 442 (2.43) 0.756
Urban, nonteaching 8028 (22.03) 3952 (21.69) 4076 (22.38) 0.115
Urban, teaching 27530 (75.56) 13833 (75.93) 13697 (75.20) 0.103
Bedsize Small 2130 (5.85) 1032 (5.66) 1098 (6.03) 0.139
Medium 6062 (16.64) 3049 (16.74) 3013 (16.54) 0.617
Large 28241 (77.51) 14137 (77.60) 14104 (77.43) 0.700
Quartiles of income First quartile 7789 (21.38) 3916 (21.50) 3873 (21.26) 0.588
Second quartile 8765 (24.06) 4407 (24.19) 4358 (23.93) 0.554
Third quartile 9307 (25.55) 4654 (25.55) 4653 (25.54) 0.998
Fourth quartile 10572 (29.02) 5241 (28.77) 5331 (29.27) 0.294
Postoperative complications 2932 (8.05) 1482 (8.13) 1450 (7.96) 0.541
All patients Derivation cohort Validation cohort P-Value*
N (%) N (%) N (%)
Comorbidities
Stroke 427 (1.17) 213 (1.17) 214 (1.17) 0.960
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TIA 20 (0.05) 13 (0.07) 7 (0.04) 0.180
Diabetes 4725 (12.97) 2370 (13.01) 2355 (12.93) 0.820
Obesity 1827 (5.01) 927 (5.09) 900 (4.94) 0.519
Coagulopathy 971 (2.67) 490 (2.69) 481(2.64) 0.772
Hyperlipidemia 7008 (19.24) 3453 (18.95) 3555 (19.52) 0.173
Chronic Renal Disease 143 (0.39) 67 (0.37) 76 (0.42) 0.450
Alcohol abuse 745 (2.04) 383 (2.10) 362 (1.99) 0.438
CAD 1432 (3.93) 718 (3.94) 714 (3.92) 0.917
Tobacco exposure 9312 (25.56) 4656 (25.56) 4656 (25.56) 0.993
CHF 813 (2.23) 409 (2.25) 404 (2.22) 0.861
Hypertension 14405 (39.54) 7137 (39.18) 7268 (39.90) 0.157
Peripheral Vascular Disease 519 (1.42) 236 (1.30) 283 (1.55) 0.038
Hydrocephalus 1955 (5.37) 990 (5.43) 965 (5.30) 0.564
Hyponatremia 2309 (6.34) 1148 (6.30) 1161 (6.37) 0.777
Seizures 2650 (7.27) 1338 (7.34) 1312 (7.20) 0.603
Pulmonary embolism 1098 (3.01) 550 (3.02) 548 (3.01) 0.953
DVT 225 (0.62) 120 (0.66) 105 (0.58) 0.316
Acute Renal Failure 472 (1.30) 231 (1.27) 241 (1.32) 0.642
IQR: interquartile range; F: female; M: male; TIA: transient ischemic attack; CAD: coronary artery disease: COPD: chronic obstructive pulmonary disease; CHF:
congestive heart failure; DVT: deep vein thrombosis.
Income quartiles were created with equal number of patients per quartile.
*Comparisons between groups were performed using the Mann–Whitney test and the Chi-square test as appropriate.
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hospitalization cost [14], especially in the setting of ex-
pensive, high-risk procedures, such as CTR. Although
regulatory bodies have set general targets for cost con-
tainment [15], their applicability in specific procedures is
still vague. This is particularly challenging, given the lim-
ited literature on factors associated with hospitalization
cost variability. Although some studies have described
the regional cost after CTR [11,12], there has been no
particular focus on the identification of drivers of
hospitalization cost, or the prediction of its magnitude.
To address this, we identified and quantified factors
associated with cost variability after craniotomy for




Mean 95% CI Median IQR Mean 95% C.I. M
31,780 31,518-32,041 24,504 4,265-44,743 32,073 31,697-32,450 2
b.
Unfavorable discharge cohort Favorable discharge coh
Mean 95% C.I. Median IQR Mean 95% C.I. M
41,446 40,898-41,993 31,208 21,403-47,662 26,504 26,292-26,716 2
95% CI: 95% confidence intervals; IQR: interquartile range.
All cost values are inflation adjusted and have been converted to 2010 price valueschanges in cost was length of stay, after controlling for
patient and hospital characteristics. Although this find-
ing is not surprising, since more cost is incurred with
longer hospitalization, its relative contribution to the
overall cost has not been studied before. Despite LOS
being a major target for cost containment, the focus
should be on excessively lengthy hospitalizations, not
justified by patient comorbidities. The comorbidities
contributing to increased LOS, in the setting of CTR,
have been identified in prior studies [16], and should be
taken into account to avoid penalizing the care of sicker
patients.
Several other factors were identified. Most import-
antly, location of the hospital was crucial in determiningValidation cohort
edian IQR Mean 95% C.I. Median IQR




based on the consumer index.
Table 3 Percent change in hospitalization cost after
craniotomy for tumor resection for every variable
included in the final predictive model
Intracranial tumors
Variable % Change in cost
Length of stay* 0.47





Urban Nonteaching hospital3 −5.73
Private insurance4 −4.97
African American5 3.87




* = Numbers represent percent change in cost for 1% change in the exposure
variable (length of stay, number of procedures).
1in comparison to Northeast; 2in comparison to small bedsize; 3in comparison
to rural hospital; 4in comparison to Medicare; 5in comparison to Caucasian; 6in
comparison to the 1st (lowest) income quartile.
Figure 2 Scatter plot demonstrating the association of the observed
cost by the parsimonious model in patients undergoing craniotomy f
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healthcare spending is widely recognized across medical
specialties [17,18]. Geographic and racial disparities re-
flect the efficiency of local healthcare delivery systems,
and the practices of individual physician groups. Cultural
characteristics, litigation environment, and established
local practices guide these trends. These result in differ-
ential resource utilization, which rarely translates in im-
proved outcomes, whereas it is associated with higher
cost. Minimizing regional disparities could contribute to
reduced spending [17,18]. In regards to CTR, it appears
that the West and Midwest were associated with signifi-
cantly higher hospitalization cost in comparison to the
Northeast, whereas the South was associated with lower
cost. Additionally, we quantified the association of num-
ber of procedures with increased cost. Higher income
was associated with higher cost, possibly secondary to
the utilization of more expensive hospitals by this popu-
lation. Lastly, hydrocephalus, other postoperative neuro-
logic complications, and coagulopathy were identified as
the most significant comorbidities contributing to higher
cost. The magnitude of these associations was described.
The proposed predictive model for hospitalization cost
after CTR was created and validated in a statistically
rigorous way. Particular attention was given to normaliz-
ing the distribution of the primary outcome, and theln cost in the validation cohort and the predicted values of ln
or tumor resection (Pearson’s rho = 0.77, P < 0.001).
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rors in our regression analysis. In addition, residual ana-
lysis confirmed the linear fit of data. The diagnostics
demonstrated that in both cohorts a significant portion
of the cost variation could be explained by the variables
included in our regression model. The model demon-
strated good predictive ability in an independent valid-
ation cohort, with the predicted and observed values
demonstrating good correlation.
Although our model cannot account for the full extent
of cost variation, since it is limited by the data available
through NIS, this is a first step in the direction of
healthcare economics at the national level. It can be uti-
lized as an adjunct in the cost containment debate, and
the creation of data-driven policies. Our model can fuel
further studies in the field and provide elements for the
design of prospective investigations.
The present study has limitations common to adminis-
trative databases. First, indication bias and residual con-
founding could account for some of the observed
associations. The 1:1 randomization of the cohort, and
the validation of the model in an independent cohort
aimed to minimize this bias. Second, several coding in-
accuracies can affect our estimates, as in other studies
involving the NIS. In addition, the number of admission
diagnoses depends on the coding accuracy for each case
and is therefore subject to the same limitations, which
are inherent to administrative data. Third, the NIS dur-
ing the years studied did not include hospitals from all
states [13]. However, the creation of the 20% sample is
done in such a way by HCUP that the hospitals included
are still diverse with respect to size, region, and aca-
demic status. In addition, the structure of NIS, and the
de-identification of the data do not allow patient follow
up overtime in a longitudinal fashion, and therefore
readmissions cannot be studied. Fourth, we are lacking
the degree of neurologic impairment at presentation of
the brain tumor patients. Fifth, some data categories
were not available for all patients. To avoid the introduc-
tion of further bias we excluded those patients from any
analysis. Sixth, we recognized postoperative neurologic
complications based on one ICD-9 (997.00), which does
not allow the identification of specific subcategories of
complications. Seventh, causality is very hard to establish
based on ecologic data. Our target was different though,
and was focused on the identification of drivers of cost
and the creation of a predictive model for it.
Conclusions
The Nationwide Inpatient Sample (NIS) is a prospective
all-payer, hospital discharge database that contains a rep-
resentative sample of all inpatient admissions to nonfed-
eral hospitals in the United States. By using this, several
socioeconomic variables, as well as patient and hospitallevel factors associated with hospitalization cost variability
after CTR were identified. Based on these data, a predict-
ive model of cost after CTR was developed and validated
in an independent cohort. Although the generalization of
these predictions should be done with caution, the model
can be utilized as an adjunct in the cost containment de-
bate and the creation of data-driven policies. This can fuel
further studies in the field and provide elements for the
design of prospective investigations.
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